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Angiogenesis, the growth of new capillary blood vessels,is critical for the growth and metastatic spread of
tumors.1 The search for tumor-derived factors that stimu-
late angiogenesis led to the identification of vascular
endothelial growth factor (VEGF, also known as VEGF-A)
as an endothelial mitogen.2 This protein had previously
been identified as vascular permeability-inducing factor
secreted by tumor cells (VPF, for vascular permeability
factor).3 The VEGF gene undergoes alternative splicing to
yield at least five different isoforms, ranging in size from
121 to 206 amino acids, of which VEGF165 is the predom-
inant form.
THE VEGF FAMILY
VEGF is now known to be the prototypic member of a
family of structurally related dimeric proteins including
VEGF-B, VEGF-C, VEGF-D, and VEGF-E, as well as pla-
cental-growth factor (PlGF) -1 and -2.4,5 VEGF is essential
for development because homozygous or heterozygous dele-
tion of the VEGF gene is embryonically lethal.6 Indeed,
VEGF family members are important in physiological angio-
genic processes in the adult including wound healing, ovula-
tion, and pregnancy, as well as pathological conditions such
as cancer.4 VEGF ligands activate angiogenic programs
through binding of several receptors. VEGFR-1 (Flt-1) binds
VEGF, VEGF-B, and PlGF -1,2 and promotes recruitment of
endothelial progenitors and monocyte migration. VEGFR-2
(Flk-1/KDR) is expressed on nearly all endothelial cells and
binds VEGF, VEGF-C, VEGF-D, and VEGF-E. Signal trans-
duction through VEGFR2 has been shown to regulate endo-
thelial cell proliferation, migration, and survival.4 In healthy
adults, expression of VEGFR-3 is limited to lymphatic endo-
thelium,7 although VEGFR-3 may also be expressed on
tumor-associated blood vessels. Through binding to VEGF-C
and VEGF-D, VEGFR-3 is thought to facilitate the outgrowth
of lymphatic vessels. Neuropilin (NRP)-1,2 have been dem-
onstrated to be coreceptors for VEGF. NRP-1 binds VEGF165
and PlGF, and NRP-2 binds VEGF165 and VEGF-C.4 Unlike
other VEGFRs, NRP-1,2 lack intracellular signaling do-
mains. Although the specific role of NRP-1,2 in angiogenesis
is not fully known, NRP-1,2 bind VEGF ligands and enhance
their affinity to other VEGFRs.8
VEGF SIGNAL TRANSDUCTION
Although VEGF-A binds VEGFR1 with a higher affin-
ity than VEGFR-2, the biological effects of VEGF-A are
thought to be mediated through VEGFR-2. On ligand bind-
ing, VEGFR-2 dimerizes, resulting in kinase activation and
autophosphorylation of tyrosine residues including Tyr951,
Tyr996, Tyr1054, Tyr1175, and Tyr1214 .9 Phosphorylation of
these residues leads to the activation of signal-transduction
molecules phospholipase C- (PLC-), PI3K, Akt, Ras, Src,
and MAPK (Figure 1). Phosphorylation of Tyr1175 results in
the binding and phosphorylation of PLC-, which subse-
quently stimulates the release of Ca2 from internal stores
and activation of protein kinase C (PKC). Activation of PKC
stimulates the Raf/MEK/ERK pathway, which promotes cell
proliferation. Ca2 mobilization and PKC activation are
thought to be key signaling events in VEGF-A–induced
vascular permeability via activation of endothelial nitric ox-
ide synthase activity.
PI3K is a heterodimer composed of a p85 regulatory
subunit and a p110 catalytic subunit and is critical in the
regulation of cell proliferation, migration, and survival.
VEGF-A has been shown to stimulate phosphorylation of p85
and enhance PI3K enzymatic activity. The mechanism by
which VEGF-A results in activation of PI3K remains unclear,
although studies have implicated a role for Src kinases,
-catenin, and VE-cadherin.10,11 VEGFR-2–induced activa-
tion of PI3K results in accumulation of phosphatidylinositol-
3,4,5-triphosphate, which induces phosphorylation of Akt/
PKB. Once activated, Akt/PKB phosphorylates and thus
inhibits proapoptotic proteins, BAD, and caspase-9.
Members of the Src family kinases, Src, Fyn, and Yes,
are expressed in endothelial cells. After VEGFR-2 autophos-
phorylation, T-cell–specific adapter binds Tyr951 and then
associates with Src. Src kinases regulate actin stress fiber
organization and may mediate VEGF-A–induced PI3K acti-
vation. Ligand binding to VEGFR-2 also triggers activation
of the Ras pathway, initiating signaling through the Raf-1–
MEK–ERK signal cascade9 known to be important in growth
factor–induced cell proliferation. This activation may occur
through multiple routes. The adaptor protein Grb2 is thought
to bind pTyr1214 on VEGFR-2, leading to stimulation of the
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guanine-nucleotide–exchange protein Sos and activation of
Ras.9 Alternatively, VEGFR2 activation may promote Shc
phosphorylation and binding to Grb2, which may induce Ras
activation.12
APPROACHES TO INHIBITING THE
VEGF PATHWAY
Several different types of agents have been developed
to target the VEGF pathway. These include monoclonal
antibodies against VEGF (i.e., bevacizumab) and proteins
that bind VEGF such as VEGF Trap, a molecule generated as
a fusion protein of the VEGFR extracellular domain and the
Fc portion of immunoglobulin G1. Other strategies to target
the VEGF pathway include antibodies that block the receptor
(IMC-1121b) as well as small-molecule inhibitors of the
receptor tyrosine kinase such as sunitinib, sorafenib, and
ZD6474 (Table 1). Receptor tyrosine kinase inhibitors are
TABLE 1. Examples of Agents in Clinical Development
Targeting the VEGF Pathway
Agent
Target within
VEGF pathway Type Company
Bevacizumaba VEGF mAB Genentech
VEGF trap VEGF EC receptor
domain
Regeneron
IMC-1121B VEGFR-2 mAb Imclone
Sunitiniba VEGFR-1,2,3 RTKI Pfizer
Sorafeniba VEGFR-2,3 RTKI Bayer
ZD6474, VEGFR-2,3 RTKI AstraZeneca
AZD2171 VEGFR-1,2,3 RTKI AstraZeneca
Vatalinib VEGFR-2 RTKI Novartis
AMG706 VEGFR-1,2,3 RTKI Amgen
Ag-013736 VEGFR-1,2,3 RTKI Pfizer
a FDA approved. RTKI, receptor tyrosine kinase inhibitor.
FIGURE 1. Signal transduction via the VEGF family. VEGF family members, VEGF, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PlGF
bind three VEGFR tyrosine kinases, resulting in dimerization, receptor autophosphorylation, and activation of downstream
signal-transduction pathways. Signal transduction through VEGFR2 is shown. Ligand binding to VEGFR2 activates signal-trans-
duction molecules phospholipase C-(PLC-), PI3K, Akt, Ras, Src, and MAPK and regulates cell proliferation, migration, sur-
vival, and vascular permeability.
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typically administered orally, and because of the structural
similarity of the different receptor tyrosine kinases, they
generally inhibit multiple kinases in addition to the VEGF
receptors. Representative agents targeting the VEGF pathway
that are currently in clinical testing are listed in Table 1. The
clinical activity of other therapeutic agents such as COX-2
inhibitors, thalidomide, and EGFR inhibitors may also be
attributable, at least in part, to reduced expression of VEGF
and other proangiogenic factors.
VEGF PATHWAY INHIBITORS:
CLINICAL RESULTS
The VEGF pathway has now been validated as a
therapeutic target by phase III randomized clinical trials for
patients with several different tumor types. In patients with
previously untreated non-small cell lung cancer, the addition
of bevacizumab to carboplatin and paclitaxel prolonged sur-
vival by approximately 2 months compared with treatment
with carboplatin and paclitaxel alone.13 Patients with squa-
mous cell histology were excluded from this trial because of
a high rate of life-theatening hemoptysis observed in phase II
testing of the same regimen. The addition of bevacizumab to
chemotherapy has provided benefit in other tumor types as
well, including colorectal, breast, and renal-cell cancer.13,14
Sorafenib and sunitinib have also demonstrated significant
clinical activity, particularly in renal-cell carcinoma.15,16 Cur-
rently, there are ongoing trials using VEGF pathway inhibi-
tors for virtually every type of tumor, and it seems likely that
they will become a standard component of treatment for a
broad range of tumor types. But despite this progress, major
challenges remain. These include developing biomarkers to
predict which patients are most likely to respond to treatment;
improving management of toxicities, particularly hemoptysis
and cardiovascular/thromboembolic complications; and un-
derstanding mechanisms of therapeutic resistance so that
combinations of VEGF inhibitors with other types of therapy
can be more rationally designed.
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